| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland; Departments of
Neurology and
Medicine, Division of Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland;
§
Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland, and Laboratory Department, Helsinki University Central Hospital, Helsinki, Finland; and
¶
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877
R6.5 (BIRR-1, Enlimomab), a murine IgG2a mAb to the human ICAM-1, inhibits leukocyte adhesion to the vascular endothelium, thereby decreasing leukocyte extravasation and inflammatory tissue injury. In initial clinical trials, R6.5 proved to be beneficial in reducing both disease activity in refractory rheumatoid arthritis and the incidence of acute rejection after kidney and liver allograft transplantations. However, adverse effects such as fever, leukopenia, or cutaneous reactions were not infrequent. We studied the effects of R6.5 on neutrophil function in whole blood samples ex vivo. Surprisingly, at the concentrations achieved in clinical trials, R6.5 activated neutrophilic granulocytes, as indicated by a significant increase in expression of the adhesion molecule ß2-integrin CD11b, a concurrent decrease in L-selectin expression, and an enhancement of the oxidative burst activity. Neutrophil activation was not exerted by an anti-ICAM-1 mAb of the IgG1 isotype, by isotype-matched, irrelevant anti-2-phenyloxazolone mAb, or by F(ab')2 fragments of R6.5. Neutrophil activation was completely inhibited by soluble complement receptor type 1. We conclude that in whole blood, R6.5 activates resting neutrophils in a complement-dependent manner. This finding can explain, at least in part, the side effects associated with R6.5 therapy.
This article has been cited by other articles:
|
|
 |
|
  D. Teoh, L. A. Johnson, T. Hanke, A. J. McMichael, and D. G. Jackson Blocking Development of a CD8+ T Cell Response by Targeting Lymphatic Recruitment of APC J. Immunol., February 15, 2009; 182(4): 2425 - 2431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yonekawa and J. M. Harlan Targeting leukocyte integrins in human diseases J. Leukoc. Biol., February 1, 2005; 77(2): 129 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J S Price, E A Warburton, and D K Menon Human cellular inflammation in the pathology of acute cerebral ischaemia J. Neurol. Neurosurg. Psychiatry, November 1, 2003; 74(11): 1476 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Merchant, D. M. Gurule, and R. S. Larson Amelioration of ischemia-reperfusion injury with cyclic peptide blockade of ICAM-1 Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1260 - H1268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mocco, T. Choudhri, J. Huang, E. Harfeldt, L. Efros, C. Klingbeil, V. Vexler, W. Hall, Y. Zhang, W. Mack, et al. HuEP5C7 as a Humanized Monoclonal Anti-E/P-Selectin Neurovascular Protective Strategy in a Blinded Placebo-Controlled Trial of Nonhuman Primate Stroke Circ. Res., November 15, 2002; 91(10): 907 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Libura, J. Drukala, M. Majka, O. Tomescu, J. M. Navenot, M. Kucia, L. Marquez, S. C. Peiper, F. G. Barr, A. Janowska-Wieczorek, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion Blood, September 18, 2002; 100(7): 2597 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.J.M. Frijns and L.J. Kappelle Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease Stroke, August 1, 2002; 33(8): 2115 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Machelska, S. A. Mousa, A. Brack, J. K. Schopohl, H. L. Rittner, M. Schafer, and C. Stein Opioid Control of Inflammatory Pain Regulated by Intercellular Adhesion Molecule-1 J. Neurosci., July 1, 2002; 22(13): 5588 - 5596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Nupponen, E. Pesonen, S. Andersson, A. Makela, R. Turunen, H. Kautiainen, and H. Repo Neutrophil Activation in Preterm Infants Who Have Respiratory Distress Syndrome Pediatrics, July 1, 2002; 110(1): 36 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Furuya, H. Takeda, S. Azhar, R. M. McCarron, Y. Chen, C. A. Ruetzler, K. M. Wolcott, T. J. DeGraba, R. Rothlein, T. E. Hugli, et al. Examination of Several Potential Mechanisms for the Negative Outcome in a Clinical Stroke Trial of Enlimomab, a Murine Anti-Human Intercellular Adhesion Molecule-1 Antibody: A Bedside-to-Bench Study Stroke, November 1, 2001; 32(11): 2665 - 2674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial Neurology, October 23, 2001; 57(8): 1428 - 1434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Nupponen, S. Andersson, A.-L. Jarvenpaa, H. Kautiainen, and H. Repo Neutrophil CD11b Expression and Circulating Interleukin-8 as Diagnostic Markers for Early-Onset Neonatal Sepsis Pediatrics, July 1, 2001; 108(1): e12 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. WELTY-WOLF, M. S. CARRAWAY, Y.-C. T. HUANG, S. G. SIMONSON, S. P. KANTROW, T. K. KISHIMOTO, and C. A. PIANTADOSI Antibody to Intercellular Adhesion Molecule 1 (CD54) Decreases Survival and Not Lung Injury in Baboons with Sepsis Am. J. Respir. Crit. Care Med., March 1, 2001; 163(3): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Becker, D. Kindrick, J. Relton, J. Harlan, R. Winn, and M. A. Yenari Antibody to the {{alpha}}4 Integrin Decreases Infarct Size in Transient Focal Cerebral Ischemia in Rats Editorial Comment Stroke, January 1, 2001; 32(1): 206 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Huang, T. F. Choudhri, C. J. Winfree, R. A. McTaggart, S. Kiss, J. Mocco, L. J. Kim, T. S. Protopsaltis, Y. Zhang, D. J. Pinsky, et al. Postischemic Cerebrovascular E-Selectin Expression Mediates Tissue Injury in Murine Stroke Editorial Comment Stroke, December 1, 2000; 31(12): 3047 - 3053. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
